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INTRODUCTION 
 
 
Kynurenic acid was first identified as early as 1853, and half a century later the 
compound was recognized as a biproduct of the tryptophan metabolism. This route of 
conversion of tryptophan was in 1947 named the kynurenine pathway. In most tissues, 
including brain, a major proportion of the tryptophan which is not used for protein synthesis is 
metabolized along the kynurneine pathway. Kynurenic acid (KYNA) is an endogenous 
metabolite in the kynurenine pathway of tryptophan degradation and is an antagonist at the 
glycine site of the N-methyl-D–aspartate (NMDA) as well as at the alpha 7 nicotinic 
cholinergic receptors. In the brain tissue KYNA is synthesised from L-kynurenine (KYN) by 
kynurenine aminotransferases (KAT) I and II. KYNA is produced by astrocytes and secreted 
into the extracellular millieu in the close vicinity of glutamatergic synapses. The KYNA 
precursor KYN is the key compound of the kynurenine pathway and is present in low 
concentrations in the blood, brain and peripheral organs and it can easily cross the blood-brain 
barrier through the large neutral amino acid transporters. 
Kynurenic acid has been suggested to be involved in the pathophysiology of several 
brain disorders, including Parkinson’s disease, Huntington’s disease, Sclerosis multiplex, 
Alzheimer’s disease and epilepsy. In addition, accumulated data indicate that massively 
released excitatory amino acids play a major role in mediating the acute ischemic neuronal 
degeneration. Thus, one of the outstanding debates in the kynurenine field is, whether 
manipulation of the kynurenine pathway can modify the levels of kynurenic acid sufficiently 
to antagonize excitatory amino acid receptors. KYNA, the only known endogenous glutamate 
receptor antagonist, displays a particularly high affinity for the NMDA receptor, however, the 
its therapeutic use is rather restricted, because KYNA has a very limited abilty to cross the 
blood-brain barrier. 
In contrast, the precursor of KYNA, KYN crosses this barrier more readily, and is 
converted to kynurenic acid in the brain tissue. Furthemore, the level of KYNA can also be 
controlled by synthetic KYNA derivatives. Some synthetic KYNA analoges penetrate the 
blood-brain barrier easily and thus can be succesfully used to elevate brain kynurenic acid 
level. During the past decade, the NMDA receptor has been identified as a primer target of 
drug development to combat neurological and psychiatric diseases which are thought to be 
directly or indirectly linked to abnormal glutamatergic neurotransmission. 
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PURPOSES 
 
 
Effects os KYNA 
 
In our in vitro experiments, we tested the effects of KYNA on the young rat 
hippocampus. Our aim was to establish a concentration-response curve for further 
comparative electrophysiological studies with the KYNA precursor KYN and KYNA 
derivative SZR-72.  
 
 
The pentylenetetrazole model 
 
To test the anticonvulsant effects of KYNA, we used an in vitro pentylenetetrazole 
(PTZ) model. PTZ, a chemical convulsant frequently utilized in the study of seizures, exerts 
its effects by binding to the picrotoxin binding site of the post-synaptic GABA-A receptor. 
 
 
The KYNA precursor: KYN 
 
Previous studies revealed that rat brain slices have the ability to convert exogenously 
added KYN to KYNA. Our study was designed to examine the conversion of KYN to KYNA 
in hippocampal rat brain slices. We applied KYN as a pretreatment in the in vitro PTZ model 
and investigated whether rat hippocampal slices have the enzimatic capacity to convert KYN 
to KYNA in amount sufficient to provide protection againts PTZ induced hyperexcitation. 
 
 
Synthetic KYNA analog: SZR-72 
 
SZR-72 is a synthetic KYNA derivative. In our in vitro studies, we tested the new 
KYNA analog in the PTZ model as to compare its anticonvulsive effects with that of the 
endogenous compound. 
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Positive neuromodulatory effects 
 
 
Studies on the mechanism of action of KYNA have demonstrated that KYNA acts as a 
competitive antagonist at the strychnine-insensitive glycine binding site of the NMDA 
receptor. In general, the concentration of KYNA required to block glutamate receptors lies in 
the range of 10-1000 µM. Thus, KYNA exerts it’s anticonvulsant properties through the 
action on excitatory amino acid receptors at non-physiological, high concentrations. Then 
again, the concentration of KYNA is about 20 nM in the rat brain. The konwledge about the 
potential physiological significance of the compound is limited. 
 In the course of ex vivo experiments on anaesthetized animals, especially when KYNA 
or glucosaminekynurenic acid was administered in low dosage, on rare occasions it was 
observed that KYNA not only did not decrease the evoked responses, but in fact increased 
their amplitudes. These unexpected observations suggest that in these cases KYNA exhibits a 
reversal effect. Accordingly, we set out to test the hypothesis that KYNA at low dosage (nM) 
acts not as a neuroinhibitor, but as a neuroexcitatory agent. Our hypothesis was tested on 
young rat hippocampal slices, under well-controlled in vitro circumstances. 
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METHODS 
 
Slice preparation 
 
Animals were killed by decapitation and sagittal slices (400 µm) were prepared from their 
hippocampi with a vibratome (Campden Instruments), in a solution composed of (in mM): 130 
NaCl, 3.5 KCl, 1 NaH2PO4, 24 NaHCO3, 1 CaCl2, 3 MgSO4 and 10 D-glucose (all from Sigma, 
Germany), saturated with 95% O2 + 5% CO2. The slices were then transferred to a Haas recording 
chamber and incubated at room temperature for 1 h in the solution used for recording (differing 
only in that it contained 3 mM CaCl2 and 1.5 mM MgSO4). 
 
 
Electrophysiology 
 
To stimulate the Schaffer collaterals (constant current, 0.2 ms pulses delivered at 0.033 
Hz), a bipolar stainless-steel microelectrode (FHC, USA) was used. The stimulus intensity was 
adjusted to between 25 and 40 µA to evoke the half-maximum response. The glass micropipettes 
(~1.5 MΩ) used for recording were filled with artificial cerebrospinal fluid (ACSF). The 
recordings were carried out in the CA1 region of the hippocampus at 34 oC. The recorded data 
were amplified (SEC-LX05, npi, Germany), filtered (1 Hz–3 kHz), acquired at a sampling rate of 
10 kHz on a pClamp8 system (Axon Instruments, USA, Digidata 1320 A/D board), and analysed 
off line with Origin software (Microcal Software, USA). 
 
 
Animals 
 
The young (postnatal days 20-30) Wistar rats used in all experiments were kept under 
constant conditions of temperature and humidity and with free access to food and water. The 
principles of animal care (NIH publication No. 85-23), and the protocol for animal care approved 
by the Hungarian Health Committee (1998) and the European Communities Council Directive 
(86/609/EEC) were followed. All efforts were made to minimize animal suffering and to reduce 
the number of animals used. 
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Statistical analysis 
 
All statistical analyses were carried out with SPSS Version 9.0. Results are expressed as 
means ± S.D. Statistical analysis was performed with one-way ANOVA followed by the post hoc 
Bonferroni test. p < 0.001 was considered statistically significant. Data for the statistical analysis 
were taken from time points where the changes in amplitude had reached their plateau 
(approximately 20-40 min after the application of each drug and 5 min prior to drug application in 
the controls). 
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DISCUSSION 
 
To test the effects of KYNA, we used an in vitro PTZ model. PTZ, a chemical 
convulsant frequently utilized in the study of seizures, exerts its effects by binding to the 
picrotoxinbinding site of the post-synaptic GABA-A receptor. PTZ is known to suppress the 
inhibitory effects of certain neurotransmitters, and especially GABA, thereby leading to an 
easier depolarization of the neurones. In our experiments, PTZ administered in vitro at 1 mM 
induced a considerable increase in the amplitude of the fEPSPs recorded from the 
hippocampal CA1 region. When applied locally in an extremely high concentration (20 mM), 
PTZ resulted in characteristic wavelets. However, KYNA administration not only decreased 
the amplitude of the hippocampal CA1 responses evoked by Schaffer collateral stimulation, 
but also afforded protection from the PTZ-induced response enhancement. The KYNA 
precursor KYN also blocked the development of the 1 mM PTZ-induced high increase in 
amplitude. To prove that the KYN→KYNA conversion did take place in our experiments and 
that it was KYNA which afforded the protection against the effects of PTZ, we applied N-
omega-nitro-l-arginine, an inhibitor of KAT I and II. After pretreatment with both KYN and 
L-NNA, the application of PTZ resulted in the marked increase in the fEPSP amplitudes, 
which indicates that the enzime inhibitor disabled KYNA production. SZR-72, a synthetic 
kynurenic acid derivative, applied in vitro, prooved to be also effective in preventing the high 
increase in fEPSP amplitudes, generated by PTZ.  
Additionally we have shown, that KYNA in submicromolar concentration range has a 
positive neuromodulatory effect. In nM concentrations, kynurenic acid does not give rise to 
inhibition, but in fact facilitates the field excitatory postsynaptic potentials, recorded from the 
hippocampal CA1 region. The administration of KYNA at below 500 nM increased the 
amplitudes of the fEPSPs. The maximum facilitatory effect of KYNA was found at 250 nM. 
This effect was reversible and could also be washed out. KYNA at 250 nM resulted in an 
average increase of 20% in the amplitudes of the fEPSPs. Similar to KYNA, the synthetic 
derivative SZR-72 also displayed a positive neuromodulatory effect in nM concentrations. 
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CONCLUSIONS 
 
 
According to our findings, a summary of following conclusions can be made: 
 
 
KYNA, applied in vitro in µM concentrations decreases the fEPSP amplitudes in the 
young rat hippocampus. KYNA administration is effective in affording protection from the 
PTZ-induced hyperexcitability. Treatment with KYNA precursor KYN, or the synthetic 
kynurenic acid derivative, SZR-72, even at very low µM concentration, has also an effect on 
enhanced neural excitability and thus support the hypothesis that manipulations of the 
kynurenine pathway might be a rewarding target in different neuronal disorders affected by 
neuronal hyperexcitation. Besides its neuroprotective and anticonvulsant effects, KYNA in 
submicromolar concentration range has a positive neuromodulatory effect. The fact that 
KYNA displays neuromodulatory effects in low nanomolar concentrations in the young rat 
hippocampus leaves the question open as to whether KYNA has a significant role in the 
developing rat brain. At early developmental stages non-functional AMPA receptors have 
been found in both CA3 and CA1 hippocampal regions. The mechanism by which these silent 
synapses are converted to functional ones is still unknown and KYNA might affords an 
answer. The in vivo significance of KYNA remains to be determined and is of peculiar 
interest. 
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